Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland

Journal of Mammary Gland Biology and Neoplasia

Volumn 13, Issue 1, 2008, Pages 55-67

  Clapp, Carmen ^a   Thebault, Stéphanie ^a   de la Escalera, Gonzalo Martínez ^a  

^a CENTRO DE FÍSICA APLICADA Y TECNOLOGÍA AVANZADA   (Mexico)

Author keywords

16K prolactin; Angiogenesis; Breast cancer; Mammary gland; Prolactin; Vasoinhibins

Indexed keywords

ANGIOPOIETIN 2; ASPARTIC PROTEINASE; CATHEPSIN D; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; ESTROGEN; FIBROBLAST GROWTH FACTOR; MASPIN; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR; PROGESTERONE; PROLACTIN; PROTEINASE; SOMATOMEDIN; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASOINHIBIN;

ANGIOGENESIS; APOPTOSIS; BLOOD VESSEL FUNCTION; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; CANCER GROWTH; CELL PROLIFERATION; ENDOTHELIUM CELL; ENZYME DEGRADATION; HUMAN; LACTATION; MALIGNANT TRANSFORMATION; MAMMARY GLAND; METASTASIS POTENTIAL; NONHUMAN; PARACRINE SIGNALING; PREGNANCY; REVIEW; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 40249084095     PISSN: 10833021     EISSN: 15737039     Source Type: Journal    
DOI: 10.1007/s10911-008-9067-7     Document Type: Review

References (160)

1. Hovey RC, Trott JF, Vonderhaar BK. Establishing a framework for the functional mammary gland: from endocrinology to morphology. J Mammary Gland Biol Neoplasia 2002;7(1):17-38.
2. Silberstein GB. Postnatal mammary gland morphogenesis. Microsc Res Tech 2001;52(2):155-62.
3. Stein T, Salomonis N, Gusterson BA. Mammary gland involution as a multi-step process. J Mammary Gland Biol Neoplasia 2007;12(1):25-35.
4. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
5. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001;61(3):253-70.
6. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. Embo J 1997;16(23):6926-35.
7. Neville MC, McFadden TB, Forsyth I. Hormonal regulation of mammary differentiation and milk secretion. J Mammary Gland Biol Neoplasia 2002;7(1):49-66.
8. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 1997;11 (2):167-78.
9. Vonderhaar BK. Prolactin involvement in breast cancer. Endocr Relat Cancer 1999;6(3):389-404.
10. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24(1):1-27.
11. Clapp C, Aranda J, Gonzalez C, Jeziorski MC, Martinez de la Escalera G. Vasoinhibins: endogenous regulators of angiogenesis and vascular function. Trends Endocrinol Metab 2006;17(8): 301-7.
12. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/ placental lactogen family in angiogenesis. J Endocrinol 2002;173 (2):219-38.
13. Hadsell DL. The insulin-like growth factor system in normal mammary gland function. Breast Dis 2003;17:3-14.
14. Matsumoto M, Nishinakagawa H, Kurohmaru M, Hayashi Y, Otsuka J. Pregnancy and lactation affect the microvasculature of the mammary gland in mice. J Vet Med Sci 1992;54(5):937-43.
15. Djonov V, Andres AC, Ziemiecki A. Vascular remodelling during the normal and malignant life cycle of the mammary gland. Microsc Res Tech 2001;52(2):182-9.
16. Richert MM, Schwertfeger KL, Ryder JW, Anderson SM. An atlas of mouse mammary gland development. J Mammary Gland Biol Neoplasia 2000;5(2):227-41.
17. Yasugi T, Kaido T, Uehara Y. Changes in density and architecture of microvessels of the rat mammary gland during pregnancy and lactation. Arch Histol Cytol 1989;52(2):115-22.
18. Abdul Awal M, Matsumoto M, Toyoshima Y, Nishinakagawa H. Ultrastructural and morphometrical studies on the endothelial cells of arteries supplying the abdomino-inguinal mammary gland of rats during the reproductive cycle. J Vet Med Sci 1996;58(1):29-34.
19. Baxter FO, Neoh K, Tevendale MC. The beginning of the end: death signaling in early involution. J Mammary Gland Biol Neoplasia 2007;12(1):3-13.
20. Walker NI, Bennett RE, Kerr JF. Cell death by apoptosis during involution of the lactating breast in mice and rats. Am J Anat 1989;185(1):19-32.
21. Benaud C, Dickson RB, Thompson EW. Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat 1998;50(2):97-116.
22. Medh RD, Thompson EB. Hormonal regulation of physiological cell turnover and apoptosis. Cell Tissue Res 2000;301(1):101-24.
23. Busso N, Huarte J, Vassalli JD, Sappino AP, Belin D. Plasminogen activators in the mouse mammary gland. Decreased expression during lactation. J Biol Chem 1989;264(13):7455-7.
24. Miller KD, Dul CL. Breast cancer: the role of angiogenesis and antiangiogenic therapy. Hematol Oncol Clin North Am 2004;18 (5):1071-86. ix.
25. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23(8):1782-90.
26. Brem SS, Gullino PM, Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977;195(4281):880-2.
27. Jensen HM, Chen I, DeVault MR, Lewis AE. Angiogenesis induced by “normal” human breast tissue: a probable marker for precancer. Science 1982;218(4569):293-5.
28. Strum JM. Angiogenic responses elicited from chorioallantoic membrane vessels by neoplastic, preneoplastic, and normal mammary tissues from GR mice. Am J Pathol 1983;111(3):282-7.
29. Lichtenbeld HC, Barendsz-Janson AF, van Essen H, Struijker Boudier H, Griffioen AW, Hillen HF. Angiogenic potential of malignant and non-malignant human breast tissues in an in vivo angiogenesis model. Int J Cancer 1998;77(3):455-9.
30. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93(4):266-76.
31. Richard DE, Berra E, Pouyssegur J. Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun 1999;266 (3):718-22.
32. Tenan M, Fulci G, Albertoni M, Diserens AC, Hamou MF, El Atifi-Borel M, et al. Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J Exp Med 2000;191(10):1789-98.
33. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001;93(4):309-14.
34. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000;83(1):63-8.
35. McLeskey SW, Zhang L, Kharbanda S, Kurebayashi J, Lippman ME, Dickson RB, et al. Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat 1996;39(1): 103-17.
36. Kim KS, Park YS. Antitumor effects of angiostatin K1-3 and endostatin genes coadministered by the hydrodynamics-based transfection method. Oncol Res 2005;15(7-8):343-50.
37. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994;263(5146):526-9.
38. Ek ET, Dass CR, Contreras KG, Choong PF. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther 2007;14(7):616-26.
39. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004;64 (9):2941-55.
40. Guinebretiere JM, Le Monique G, Gavoille A, Bahi J, Contesso G. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 1994;86(8):635-6.
41. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324(1):1-8.
42. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84(24):1875-87.
43. Dabrosin C. Sex steroid regulation of angiogenesis in breast tissue. Angiogenesis 2005;8(2):127-36.
44. Rossiter H, Barresi C, Ghannadan M, Gruber F, Mildner M, Fodinger D, et al. Inactivation of VEGF in mammary gland epithelium severely compromises mammary gland development and function. Faseb J 2007;21(14):3994-4004.
45. Bando H. Vascular endothelial growth factor and bevacitumab in breast cancer. Breast Cancer 2007;14(2):163-73.
46. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 2000;60(12):3183-90.
47. Wu J, Richer J, Horwitz KB, Hyder SM. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Res 2004;64(6):2238-44.
48. Miele C, Rochford JJ, Filippa N, Giorgetti-Peraldi S, Van Obberghen E. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem 2000;275(28):21695-702.
49. Goldhar AS, Vonderhaar BK, Trott JF, Hovey RC. Prolactininduced expression of vascular endothelial growth factor via Egr-1. Mol Cell Endocrinol 2005;232(1-2):9-19.
50. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997;138 (3):707-17.
51. Yamauchi M, Imajoh-Ohmi S, Shibuya M. Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle. Cancer Sci 2007;98(9):1491-7.
52. Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 2000;37(3):209-18.
53. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000;6(2):196-9.
54. Shao ZM, Radziszewski WJ, Barsky SH. Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms. Cancer Lett 2000;157(2):133-44.
55. Mirkin S, Wong BC, Archer DF. Effects of 17beta-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messenger RNA in breast cancer cells. Int J Gynecol Cancer 2006;16(2):560-3.
56. Uray IP, Liang Y, Hyder SM. Estradiol down-regulates CD36 expression in human breast cancer cells. Cancer Lett 2004;207 (1):101-7.
57. Li Z, Shi HY, Zhang M. Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis. Oncogene 2005;24(12):2008-19.
58. Volpert OV, Stellmach V, Bouck N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat 1995;36(2):119-26.
59. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001;98(22):12485-90.
60. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 2006;26(4):716-28.
61. Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36(1):128-37.
62. Briozzo P, Badet J, Capony F, Pieri I, Montcourrier P, Barritault D, et al. MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res 1991;194(2):252-9.
63. Liaudet-Coopman E, Beaujouin M, Derocq D, Garcia M, Glondu-Lassis M, Laurent-Matha V, et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 2006;237(2):167-79.
64. Macotela Y, Aguilar MB, Guzman-Morales J, Rivera JC, Zermeno C, Lopez-Barrera F, et al. Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. J Cell Sci 2006;119(Pt 9):1790-800.
65. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001;86(1):346-55.
66. Gaytan F, Morales C, Bellido C, Aguilar E, Sanchez-Criado JE. Role of prolactin in the regulation of macrophages and in the proliferative activity of vascular cells in newly formed and regressing rat corpora lutea. Biol Reprod 1997;57(2):478-86.
67. Struman I, Bentzien F, Lee H, Mainfroid V, D’Angelo G, Goffin V, et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone familymembers on angiogenesis: an efficientmechanism for the regulation of angiogenesis. Proc Natl Acad Sci U S A 1999;96(4):1246-51.
68. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993;133(3): 1292-9.
69. Ge G, Fernandez CA, Moses MA, Greenspan DS. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proc Natl Acad Sci U S A 2007;104(24): 10010-5.
70. Ueda E, Ozerdem U, Chen YH, Yao M, Huang KT, Sun H, et al. A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocr Relat Cancer 2006;13(1):95-111.
71. Ko JY, Ahn YL, Cho BN. Angiogenesis and white blood cell proliferation induced in mice by injection of a prolactin-expressing plasmid into muscle. Mol Cells 2003;15(2):262-70.
72. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128(3):589-600.
73. Clapp C, Lopez-Gomez FJ, Nava G, Corbacho A, Torner L, Macotela Y, et al. Expression of prolactin mRNA and of prolactin-like proteins in endothelial cells: evidence for autocrine effects. J Endocrinol 1998;158(1):137-44.
74. Grosdemouge I, Bachelot A, Lucas A, Baran N, Kelly PA, Binart N. Effects of deletion of the prolactin receptor on ovarian gene expression. Reprod Biol Endocrinol 2003;1:12.
75. Duenas Z, Torner L, Corbacho AM, Ochoa A, Gutierrez-Ospina G, Lopez-Barrera F, et al. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules. Invest Ophthalmol Vis Sci 1999;40(11):2498-505.
76. Ochoa A, Montes de Oca P, Rivera JC, Duenas Z, Nava G, de La Escalera GM, et al. Expression of prolactin gene and secretion of prolactin by rat retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 2001;42(7):1639-45.
77. Clapp C, Weiner RI. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 1992;130(3):1380-6.
78. Merkle CJ, Schuler LA, Schaeffer RC Jr., Gribbon JM, Montgomery DW. Structural and functional effects of high prolactin levels on injured endothelial cells: evidence for an endothelial prolactin receptor. Endocrine 2000;13(1):37-46.
79. Ricken AM, Traenkner A, Merkwitz C, Hummitzsch K, Grosche J, Spanel-Borowski K. The short prolactin receptor predominates in endothelial cells of micro-and macrovascular origin. J Vasc Res 2007;44(1):19-30.
80. Ferrara N, Clapp C, Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 1991;129 (2):896-900.
81. Malaguarnera L, Pilastro MR, Quan S, Ghattas MH, Yang L, Mezentsev AV, et al. Significance of heme oxygenase in prolactin-mediated cell proliferation and angiogenesis in human endothelial cells. Int J Mol Med 2002;10(4):433-40.
82. Duenas Z, Rivera JC, Quiroz-Mercado H, Aranda J, Macotela Y, Montes de Oca P, et al. Prolactin in eyes of patients with retinopathy of prematurity: implications for vascular regression. Invest Ophthalmol Vis Sci 2004;45(7):2049-55.
83. Corbacho AM, Macotela Y, Nava G, Torner L, Duenas Z, Noris G, et al. Human umbilical vein endothelial cells express multiple prolactin isoforms. J Endocrinol 2000;166(1):53-62.
84. Malaguarnera L, Imbesi RM, Scuto A, D’Amico F, Licata F, Messina A, et al. Prolactin increases HO-1 expression and induces VEGF production in human macrophages. J Cell Biochem 2004;93(1):197-206.
85. Deramaudt BM, Braunstein S, Remy P, Abraham NG. Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis. J Cell Biochem 1998;68 (1):121-7.
86. Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AM, et al. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 2000;192(7): 1015-26.
87. Srivastava RK, Gu Y, Ayloo S, Zilberstein M, Gibori G. Developmental expression and regulation of basic fibroblast growth factor and vascular endothelial growth factor in rat decidua and in a decidual cell line. J Mol Endocrinol 1998;21 (3):355-62.
88. Too CK, Knee R, Pinette AL, Li AW, Murphy PR. Prolactin induces expression of FGF-2 and a novel FGF-responsive NonO/ p54nrb-related mRNA in rat lymphoma cells. Mol Cell Endocrinol 1998;137(2):187-95.
89. Malaguarnera L, Imbesi R, Di Rosa M, Scuto A, Castrogiovanni P, Messina A, et al. Action of prolactin, IFN-gamma, TNF-alpha and LPS on heme oxygenase-1 expression and VEGF release in human monocytes/macrophages. Int Immunopharmacol 2005;5 (9):1458-69.
90. Yu JL, Rak JW. Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res 2003;5(2):83-8.
91. Dogusan Z, Hooghe R, Verdood P, Hooghe-Peters EL. Cytokinelike effects of prolactin in human mononuclear and polymorphonuclear leukocytes. J Neuroimmunol 2001;120(1-2):58-66.
92. Yu-Lee LY. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res 2002;57:435-55.
93. Montes de Oca P, Macotela Y, Nava G, Lopez-Barrera F, de la Escalera GM, Clapp C. Prolactin stimulates integrinmediated adhesion of circulating mononuclear cells to endothelial cells. Lab Invest 2005;85(5):633-42.
94. Mills DE, Ward RP. Effect of prolactin on blood pressure and cardiovascular responsiveness in the rat. Proc Soc Exp Biol Med 1986;181(1):3-8.
95. Bryant EE, Douglas BH, Ashburn AD. The effect of prolactin on blood pressure, blood volume, and angiotensin response. J Lab Clin Med 1971;78(5):795-6.
96. Mati JK, Mugambi M, Odipo WS, Nguli K. Prolactin and hypertension. Am J Obstet Gynecol 1977;127(6):616-9.
97. Horrobin DF, Manku MS, Burstyn PG. Effect of intravenous prolactin infusion on arterial blood pressure in rabbits. Cardiovasc Res 1973;7(5):585-7.
98. Manku MS, Nassar BA, Horrobin DF. Effects of prolactin on the responses of rat aortic and arteriolar smooth-muscle preparations to noradrenaline and angiotensin. Lancet 1973;2(7836):991-4.
99. Gonzalez C, Corbacho AM, Eiserich JP, Garcia C, Lopez-Barrera F, Morales-Tlalpan V, et al. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 2004;145(12):5714-22.
100. Molinari C, Grossini E, Mary DA, Uberti F, Ghigo E, Ribichini F, et al. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology 2007;148(8):4080-90.
101. Grossini E, Molinari C, Battaglia A, Mary DA, Ribichini F, Surico N, et al. Human placental lactogen decreases regional blood flow in anesthetized pigs. J Vasc Res 2006;43(2):205-13.
102. Vacca G, Battaglia A, Chiorboli E, Grossini E, Mary DA, Molinari C, et al. Haemodynamic effects of the intravenous administration of growth hormone in anaesthetized pigs. Pflugers Arch 1998;436(2):159-67.
103. Rosenfeld CR. Distribution of cardiac output in ovine pregnancy. Am J Physiol 1977;232(3):H231-5.
104. Hanwell A, Linzell JL. The time course of cardiovascular changes in lactation in the rat. J Physiol 1973;233(1):93-109.
105. Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 2003;149(3):187-93.
106. Baldocchi RA, Tan L, King DS, Nicoll CS. Mass spectrometric analysis of the fragments produced by cleavage and reduction of rat prolactin: evidence that the cleaving enzyme is cathepsin D. Endocrinology 1993;133(2):935-8.
107. Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. Embo J 1995;14(15):3599-608.
108. Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, Garcia M, et al. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 2002;21(38):5951-5.
109. Piwnica D, Touraine P, Struman I, Tabruyn S, Bolbach G, Clapp C, et al. Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. Mol Endocrinol 2004;18(10):2522-42.
110. Piwnica D, Fernandez I, Binart N, Touraine P, Kelly PA, Goffin V.A new mechanism for prolactin processing into 16K PRL by secreted cathepsin D. Mol Endocrinol 2006;20(12):3263-78.
111. Erdmann S, Ricken AM, Merkwitz C, Struman I, Castino R, Hummitzsch K, et al. The Expression of prolactin and its cathepsin d-mediated cleavage in the bovine corpus luteum vary with the oestrous cycle. Am J Physiol Endocrinol Metab 2007;293(5):E1365-77.
112. Cosio G, Jeziorski MC, Lopez-Barrera F, De La Escalera GM, Clapp C. Hypoxia inhibits expression of prolactin and secretion of cathepsin-D by the GH4C1 pituitary adenoma cell line. Lab Invest 2003;83(11):1627-36.
113. Lkhider M, Castino R, Bouguyon E, Isidoro C, Ollivier-Bousquet M. Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions. J Cell Sci 2004;117(Pt 21):5155-64.
114. Gonzalez C, Parra A, Ramirez-Peredo J, Garcia C, Rivera JC, Macotela Y, et al. Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia. Lab Invest 2007;87(10):1009-17.
115. Ge G, Greenspan DS. Developmental roles of the BMP1/TLD metalloproteinases. Birth Defects Res C Embryo Today 2006;78 (1):47-68.
116. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004;16(5):558-64.
117. Khurana S, Kuns R, Ben-Jonathan N. Heparin-binding property of human prolactin: a novel aspect of prolactin biology. Endocrinology 1999;140(2):1026-9.
118. Harper J, Klagsbrun M. Cartilage to bone-angiogenesis leads the way. Nat Med 1999;5(6):617-8.
119. Corbacho AM, Nava G, Eiserich JP, Noris G, Macotela Y, Struman I, et al. Proteolytic cleavage confers nitric oxide synthase inducing activity upon prolactin. J Biol Chem 2000;275(18): 13183-6.
120. Lorenson MY, Jacobs LS. Depletion of bovine pituitary prolactin by cysteamine involves a thiol:disulfide mechanism. Endocrinology 1984;115(4):1492-5.
121. Galfione M, Luo W, Kim J, Hawke D, Kobayashi R, Clapp C, et al. Expression and purification of the angiogenesis inhibitor 16-kDa prolactin fragment from insect cells. Protein Expr Purif 2003;28(2):252-8.
122. Tabruyn SP, Sorlet CM, Rentier-Delrue F, Bours V, Weiner RI, Martial JA, et al. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol Endocrinol 2003;17(9):1815-23.
123. Aranda J, Rivera JC, Jeziorski MC, Riesgo-Escovar J, Nava G, Lopez-Barrera F, et al. Prolactins are natural inhibitors of angiogenesis in the retina. Invest Ophthalmol Vis Sci 2005;46 (8):2947-53.
124. Pan H, Nguyen NQ, Yoshida H, Bentzien F, Shaw LC, Rentier-Delrue F, et al. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci 2004;45(7):2413-9.
125. Bentzien F, Struman I, Martini JF, Martial J, Weiner R. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(−/−) mice. Cancer Res 2001;61(19):7356-62.
126. Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, et al. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 2003;63(2):386-93.
127. Nguyen NQ, Cornet A, Blacher S, Tabruyn SP, Foidart JM, Noel A, et al. Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Mol Ther 2007;15(12):2094-100.
128. Lee S-H, Kunz J, Lin S-H, Yu-Lee L-Y. 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Res 2007;67 (22):11045-53.
129. Martini JF, Piot C, Humeau LM, Struman I, Martial JA, Weiner RI. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol Endocrinol 2000;14 (10):1536-49.
130. Tabruyn SP, Nguyen NQ, Cornet AM, Martial JA, Struman I. The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases. Mol Endocrinol 2005;19(7):1932-42.
131. Lee SH, Nishino M, Mazumdar T, Garcia GE, Galfione M, Lee FL, et al. 16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1/IFN regulatory factor-1 pathway. Cancer Res 2005;65(17):7984-92.
132. D’Angelo G, Martini JF, Iiri T, Fantl WJ, Martial J, Weiner RI. 16K human prolactin inhibits vascular endothelial growth factorinduced activation of Ras in capillary endothelial cells. Mol Endocrinol 1999;13(5):692-704.
133. D’Angelo G, Struman I, Martial J, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci U S A 1995;92(14):6374-8.
134. Ziche M, Morbidelli L. Nitric oxide and angiogenesis. J Neurooncol 2000;50(1-2):139-48.
135. Lee H, Struman I, Clapp C, Martial J, Weiner RI. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology 1998;139(9):3696-703.
136. Han Q, Leng J, Bian D, Mahanivong C, Carpenter KA, Pan ZK, et al. Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells. J Biol Chem 2002;277(50):48379-85.
137. Abu-Soud HM, Stuehr DJ. Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. Proc Natl Acad Sci U S A 1993;90(22):10769-72.
138. Tabruyn SP, Sabatel C, Nguyen NQ, Verhaeghe C, Castermans K, Malvaux L, et al. The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. Mol Endocrinol 2007;21(6): 1422-9.
139. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003;54(4):469-87.
140. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002;53(4 Pt 1):503-14.
141. van der Vliet A, Eiserich JP, Shigenaga MK, Cross CE. Reactive nitrogen species and tyrosine nitration in the respiratory tract: epiphenomena or a pathobiologic mechanism of disease? Am J Respir Crit Care Med 1999;160(1):1-9.
142. Green KA, Lund LR. ECM degrading proteases and tissue remodelling in the mammary gland. Bioessays 2005;27(9):894-903.
143. Baldocchi RA, Tan L, Nicoll CS. Processing of rat prolactin by rat tissue explants and serum in vitro. Endocrinology 1992;130 (3):1653-9.
144. Clapp C. Analysis of the proteolytic cleavage of prolactin by the mammary gland and liver of the rat: characterization of the cleaved and 16K forms. Endocrinology 1987;121(6):2055-64.
145. Lkhider M, Delpal S, Le Provost F, Ollivier-Bousquet M. Rat prolactin synthesis by lactating mammary epithelial cells. FEBS Lett 1997;401(2-3):117-22.
146. Rochefort H, Garcia M, Glondu M, Laurent V, Liaudet E, Rey JM, et al. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 2000;291(2): 157-70.
147. Owen JL, Iragavarapu-Charyulu V, Lopez DM. T cell-derived matrix metalloproteinase-9 in breast cancer: friend or foe? Breast Dis 2004;20:145-53.
148. Baldocchi RA, Tan L, Hom YK, Nicoll CS. Comparison of the ability of normal mouse mammary tissues and mammary adenocarcinoma to cleave rat prolactin. Proc Soc Exp Biol Med 1995;208(3):283-7.
149. Liby K, Neltner B, Mohamet L, Menchen L, Ben-Jonathan N. Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res Treat 2003;79 (2):241-52.
150. Coskun U, Gunel N, Toruner FB, Sancak B, Onuk E, Bayram O, et al. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer. Neoplasma 2003;50(1):41-6.
151. Sancak B, Coskun U, Gunel N, Onuk E, Cihan A, Karamercan A, et al. No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery. Intern Med J 2004;34(6):310-5.
152. Coleman-Krnacik S, Rosen JM. Differential temporal and spatial gene expression of fibroblast growth factor family members during mouse mammary gland development. Mol Endocrinol 1994;8(2):218-29.
153. Shi YH, Bingle L, Gong LH, Wang YX, Corke KP, Fang WG. Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells. Pathology 2007;39 (4):396-400.
154. Pietras RJ. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J 2003;9(5):361-73.
155. Furstenberger G, Morant R, Senn HJ. Insulin-like growth factors and breast cancer. Onkologie 2003;26(3):290-4.
156. Nakamura J, Lu Q, Aberdeen G, Albrecht E, Brodie A. The effect of estrogen on aromatase and vascular endothelial growth factor messenger ribonucleic acid in the normal nonhuman primate mammary gland. J Clin Endocrinol Metab 1999;84(4): 1432-7.
157. Calvo A, Yokoyama Y, Smith LE, Ali I, Shih SC, Feldman AL, et al. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer 2002;101(3):224-34.
158. Benson JR. Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol 2004;5(4):229-39.
159. Indraccolo S, Gola E, Rosato A, Minuzzo S, Habeler W, Tisato V, et al. Differential effects of angiostatin, endostatin and interferonalpha(1) gene transfer on in vivo growth of human breast cancer cells. Gene Ther 2002;9(13):867-78.
160. Chen QR, Kumar D, Stass SA, Mixson AJ. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 1999;59(14): 3308-12.